

RNAi Technologies and Global Markets

Market Research Report | 2024-06-25 | 118 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope

The scope of this study encompasses an investigation of the ribonucleic acid interference (RNAi) technology market. BCC Research analyzes RNAi technology based on technology type: tools and reagents, diagnostics, therapeutics, and agriculture. BCC Research determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next six years. The report provides a detailed analysis of the market's drivers, restraints, challenges, and opportunities. It includes company profiles of key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides detailed information on emerging technologies and new developments in the market; examines the regulatory landscape; provides a patent and pipeline analysis; and discusses ESG developments, the investment outlook, and deals within the market.

Report Includes

- 26 data tables and 53 additional tables
- An overview of the global market for RNAi technologies
- Analysis of global market trends, featuring revenue data for 2021- 2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
- Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by type, therapeutic area, delivery method, and region
- A look at innovations, technological advances, and recent product launches in the RNAi market
- Analysis of the industry's regulatory framework and policies
- A discussion of ESG challenges and ESG practices in the RNAi technologies industry
- An analysis of the key companies' market shares, proprietary technologies, and strategic alliances
- Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Novartis AG, Thermo Fisher Scientific Inc., and Revvity Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Executive Summary

Summary:

The global market for RNAi technology is estimated to increase from \$2.1 billion in 2023 to reach \$4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Background: Genetic Material

RNA Interference Overview

RNA Interference: Mechanism of Action

Initiation Phase

Effector Phase

Small Interfering RNAs (siRNAs)

MicroRNAs (miRNAs)

Small Hairpin RNAs (shRNAs)

Chapter 3 Market Dynamics

Global Market Dynamics

Market Drivers

Increasing Prevalence of Chronic Disease

Increasing Approval of RNAi Products

Advancements in RNAi Delivery Systems

Increasing Strategic Initiatives

Convenient Dosing

Market Restraints

High Treatment Costs

Lack of Awareness

Market Opportunities

Expansion of Disease Targets

Combination Therapies

Untapped Genetic Targets

Chapter 4 Emerging Technologies and Developments

Therapeutics

Diagnostics

Circulating miRNA Diagnostics for Non-invasive Health Monitoring

Agriculture

Chapter 5 Pipeline Analysis

Chapter 6 Patent Analysis

Patent Analysis

Chapter 7 Market Segmentation Analysis

Segmentation Breakdown

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Overview
Market Analysis by Technology
Therapeutics
RNAi Therapeutics Market, by Region
RNAi Therapeutics Market, by Therapeutic Area
RNAi Therapeutics Market, by Delivery Method
Diagnostics
Reagents and Tools
Agriculture
Geographic Breakdown
Market Analysis by Region
North America
Europe
Emerging Markets
Chapter 8 Competitive Intelligence
Strategic Initiatives
Competitive Analysis
Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective
Introduction to ESG
Sustainability in RNAi Technology Industry: An ESG Perspective
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study
Concluding Remarks from BCC
Chapter 10 Appendix
Methodology
Acronyms
Sources
Company Profiles
ALNYLAM PHARMACEUTICALS INC.
ARROWHEAD PHARMACEUTICALS INC.
ARBUTUS BIOPHARMA CORP.
BAYER AG
MERCK KGAA
NOVARTIS AG
NOVO NORDISK A/S
OLIX PHARMACEUTICALS INC.
QIAGEN
REVVITY INC.
SILENCE THERAPEUTICS
SIRNAOMICS
SYLENTIS S.A.
SWITCH THERAPEUTICS
THERMO FISHER SCIENTIFIC INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

RNAi Technologies and Global Markets

Market Research Report | 2024-06-25 | 118 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

